Search

Your search keyword '"Mahfoud, F"' showing total 280 results

Search Constraints

Start Over You searched for: Author "Mahfoud, F" Remove constraint Author: "Mahfoud, F" Topic hypertension Remove constraint Topic: hypertension
280 results on '"Mahfoud, F"'

Search Results

1. Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.

2. Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial.

3. Pyridoxal-5'-phosphate: A cost-effective treatment candidate for hypertensive patients?

4. Arterial hypertension-clinical trials update 2024.

5. A novel, proof-of-concept radiofrequency renal denervation strategy to improve procedural efficiency: 12-month results from the SPYRAL DYSTAL pilot study.

6. Autonomic Nervous System: A Therapeutic Target for Cardiac End-Organ Damage in Hypertension.

7. Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes.

8. Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the Global Paradise System registry study design.

10. Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes.

11. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.

12. Impact of Renal Denervation on Urinary Peptide-Based Biomarkers in Hypertension.

13. Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.

14. Renal denervation in the management of hypertension.

15. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.

16. Management of Resistant Hypertension.

17. The current position of β-blockers in hypertension: guidelines and clinical practice.

18. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).

19. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.

21. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.

22. Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry.

23. Arterial Hypertension-clinical trials update 2023.

24. Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE.

25. Radio frequency-based renal denervation: a story of simplicity?

26. Hypertension management in patients with cardiovascular comorbidities.

27. Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.

28. Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study.

29. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.

30. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

31. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.

33. Translational value of preclinical models for renal denervation: a histological comparison of human versus porcine renal nerve anatomy.

34. Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia.

35. New perspectives for hypertension management: progress in methodological and technological developments.

36. Medication adherence in hypertension: lessons learned from renal denervation trials.

37. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial.

38. Sex differences in arterial hypertension.

39. Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation.

40. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.

41. Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range.

42. Renal denervation prevents subclinical atrial fibrillation in patients with hypertensive heart disease: Randomized, sham-controlled trial.

43. Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial.

44. Histological evidence supporting the durability of successful radiofrequency renal denervation in a normotensive porcine model.

45. Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome.

46. Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.

47. Arterial hypertension - clinical trials update 2022.

48. Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study.

49. Effects of Medical Face Masks on Physical Performance in Patients With Coronary Artery Disease or Hypertension.

50. A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model.

Catalog

Books, media, physical & digital resources